Adam M. Spivak, M.D.

Bio

Dr. Spivak joined the Division of Infectious Diseases as a Visiting Instructor in the fall of 2011. He cares for HIV patients as a member of the Clinic 1A staff at the University of Utah Hospital and attends on the inpatient Infectious Diseases consult service at both the University and VA Hospitals.

Board Certification and Academic Information

Board Certification and Academic Information

Academic Office Locations

Academic Bio

Dr. Spivak joined the Division of Infectious Diseases in October 2011 after completing Infectious Diseases fellowship training at Johns Hopkins University School of Medicine. His primary focus is on translational research exploring HIV persistence and strategies for viral eradication.

During fellowship, Dr. Spivak spent three years in the laboratory of Dr. Robert Siliciano where he studied cellular reservoirs of HIV and helped to run a pilot clinical trial of a novel HIV eradication strategy. In May 2011, Dr. Spivak was awarded a Bill and Melinda Gates Foundation Grand Challenges Explorations Grant for a research proposal describing an in vitro screening assay to identify compounds able to selectively induce apoptosis in HIV infected cells.

At the University of Utah, Dr. Spivak will spend the majority of his time in the laboratory of Vicente Planelles in the Department of Pathology. Working with members of the Planelles lab, he will continue his ongoing research into the nature of HIV persistence. He cares for HIV patients as a member of the Clinic 1A staff at the University of Utah Hospital and attends on the inpatient Infectious Diseases consult service at both the University and VA Hospitals.

Education History

Selected Provider Publications

Journal Article

1. Martins LJ, Bonczkowski P, Spivak AM, De Spiegelaere W, Novis CL, DePaula-Silva AB, Malatinkova E, Typsteen W, Bosque A, Vanderkerckhove L, Planelles V (2016). Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus. AIDS Res Hum Retroviruses, 32(2), 187-193.
2. Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V (2015). Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients. Antimicrob Agents Chemother, 59(10), 5984-91.
3. Pache L, Dutra MS, Spivak AM, Marlett JM, Murry JP, Hwang Y, Maestre AM, Manganaro L, Vamos M, Teriete P, Martins LJ, Konig R, Simon V, Bosque A, Fernandez-Sesma A, Cosford ND, Bushman FD, Young JA, Planelles V, Chanda SK (2015). BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. Cell Host Microbe, 18(3), 345-53.
4. Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, Emad F, Buckheit R 3rd, McCance-Katz EF, Lai J, Kennedy M, Chander G, Siliciano RF, Siliciano JD, Deeks SG (2014). A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis, 58(6), 883-90.
5. Barber AE, Norton JP, Spivak AM, Mulvey MA (2013). Urinary tract infections: current and emerging management strategies. Clin Infect Dis, 57(5), 719-24.
6. Weil AF, Ghosh D, Zhou Y, Seiple L, McMahon MA, Spivak AM, Siliciano RF, Stivers JT (2013). Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration. Proc Natl Acad Sci U S A, 110(6), E448-57.
7. Spivak AM, Salgado M, Rabi SA, OConnell KA, Blankson JN (2011). Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors. J Virol, 85(19), 10399-403.
8. Spivak AM, Rabi SA, McMahon MA, Shan L, Sedaghat AR, Wilke CO, Siliciano RF (2011). Short communication: dynamic constraints on the second phase compartment of HIV-infected cells. AIDS Res Hum Retroviruses, 27(7), 759-61.
9. Gaillard S, Dinoso JB, Marsh JA, DeZern AE, OConnell KA, Spivak AM, Alwood K, Durand CM, Ambinder RF, Blankson JN (2011). Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy. J Clin Virol, 51(3), 195-8.
10. Spivak AM, Brennan TP, OConnell KA, Sydnor E, Williams TM, Siliciano RF, Gallant JE, Blankson JN (2010). A case of seronegative HIV-1 infection. J Infect Dis, 201(3), 341-5.

Review

1. Spivak AM, Planelles V (2016). HIV-1 Eradication: Early Trials (and Tribulations). [Review]. Trends Mol Med, 22(1), 10-27.
2. Spivak AM, Sydnor ER, Blankson JN, Gallant JE (2010). Seronegative HIV-1 infection: a review of the literature. [Review]. AIDS, 24(10), 1407-14.
3. Pradilla G, Nagahama Y, Spivak AM, Bydon A, Rigamonti D (2010). Spinal epidural abscess: current diagnosis and management. [Review]. Curr Infect Dis Rep, 12(6), 484-91.

Letter

1. Spivak AM, Siliciano RF (2010). Using highly active antiretroviral therapy to decrease perioperative HIV-1 transmission risk [Letter to the editor]. AIDS, 24(10), 1603-4; author reply 1604.

Poster

1. Spivak AM, Bosque A, Planelles V (2014). An In Vitro Compound Screen for Selective Apoptosis Induction In HIV-1 Infected Resting CD4+ T Cells. Poster session presented at 2014 Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA.
2. Spivak AM, Andrade A, Hoh R, Bacchetti P, Eisele E, Buckheit III R, Lai J, Siliciano J, Siliciano R, Deeks S (2012). Safety and Feasibility of Using Disulfiram to Enhance HIV Transcription among Long-term ARV-treated Adults: Preliminary Results from a Pilot Study. Poster session presented at 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
3. Spivak AM, Gaillard S, Dinoso J, Marsh J, Blankson J (2011). Sustained Elite Suppression of Replication Competent HIV-1 in a Patient Treated with Rituximab Based Chemotherapy. [Abstract 291]. Poster session presented at 18th CROI, Boston, MA.
4. Spivak AM, Reza A, McMahon M, Sedaghat A, Siliciano RF (2009). Understanding Decay of Viremia in Patients on Raltegravir. . [Abstract 552]. Poster session presented at 16th CROI, Montreal, Canada.

Video